Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients
| Autor: | Xavier Pivot, Cathie Fischbach, Julie Leblanc, Hugo Herrscher, Michal Kalish-Weindling, Michel Velten, Thierry Petit, Delphine Exinger |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
0301 basic medicine Oncology Cancer Research medicine.medical_specialty Pyridines Triple Negative Breast Neoplasms Palbociclib Piperazines 03 medical and health sciences 0302 clinical medicine Breast cancer Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Neoplasm Metastasis Fulvestrant Aged Neoplasm Staging Everolimus business.industry Middle Aged Prognosis medicine.disease Metastatic breast cancer Treatment Outcome 030104 developmental biology Hormone receptor 030220 oncology & carcinogenesis Retreatment Cohort Female business Follow-Up Studies medicine.drug Hormone |
| Zdroj: | Breast Cancer Research and Treatment. 179:371-376 |
| ISSN: | 1573-7217 0167-6806 |
| DOI: | 10.1007/s10549-019-05439-x |
| Popis: | We report the results of a retrospective analysis of the fulvestrant and palbociclib combination within a temporary authorization of use (TAU) program in 77 heavily pretreated patients with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer. All patients who received the fulvestrant and palbociclib combination within this TAU program were included. Toxicities were graded using the CTCAE v5 scale. The majority of patients (62.3%) were previously treated with the mTOR inhibitor everolimus. The median number of previous treatments for their metastatic disease was 4. With a median follow-up of 14 months, the median progression-free survival (PFS) was 7.6 months. The median PFS significantly (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink